Park Ha Biological Technology (BYAH) Current Deferred Revenue (2023 - 2026)

Park Ha Biological Technology (BYAH) has reported Current Deferred Revenue for 4 consecutive years, with $194968.0 the latest figure, recorded in Q2 2026.

• Quarterly Current Deferred Revenue rose 64.84% year-over-year to $194968.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $194968.0 (up 64.84% YoY) and the FY2025 annual result came in at $194753.0, down 40.25% from the prior year.
• Current Deferred Revenue steadied at $194968.0 in Q2 2026 per BYAH's latest filing, from $194753.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for BYAH reached as high as $325924.0 in Q4 2024 and fell as low as $118277.0 in Q2 2025.
• A 4-year average of $216894.2 and a median of $194968.0 in 2026 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue sank 40.25% — and 2026, when it soared 64.84%.
• Year by year, Current Deferred Revenue stood at $250549.0 in 2023, then soared by 30.08% to $325924.0 in 2024, then sank by 40.25% to $194753.0 in 2025, then gained by 0.11% to $194968.0 in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $194968.0, $194753.0, and $118277.0 for Q2 2026, Q4 2025, and Q2 2025 respectively.